Earnings Ahead

NBIX - Neurocrine Biosciences Inc.

95.56 1.54 1.64

Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc.

About

Profile

Neurocrine’s management team participates in industry conferences providing presentations on company updates and progress on research and development activities. The company conducts webcasts and conference calls for these conferences and provides finan


Headquarters

San Diego, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

NBIX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.03, revenue of $515.2M misses by $3.19M
  • Neurocrine Biosciences Q4 2023 Earnings Preview
  • Big Pharma earnings season in spotlight amid positive sentiment
  • Goldman says these stocks with weak pricing power can outperform
  • Biogen, Neurocrine, and more are Bairds top picks for biotech in 2024
  • Bristol-Karuna deal: What other biotechs might be in M&A crosshairs?
  • Top overweight stocks with high growth and low volume - MS
  • Citi starts Neurocrine at neutral, sees stock as fairly valued
  • Neurocrine gets FDA breakthrough therapy status for crinecerfont
  • The most crowded pharma longs and shorts, according to UBS
  • Neurocrine Biosciences executive discloses sale of over 10K shares
  • Neurocrine settles all patent disputes related to movement disorder therapy
  • Neurocrine reports Phase 2 study failures for two drug candidates
  • Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.21, revenue of $498.8M beats by $19.77M
  • Neurocrine Biosciences Q3 2023 Earnings Preview
  • Neurocrine says new Ingrezza version is under FDA review
  • Neurocrine gains after Phase 3 win for genetic disorder drug
  • Neurocrine releases new data on Ingrezza for Huntington's disease chorea
  • Neurocrine nabs FDA label expansion for Ingrezza
  • Neurocrine Biosciences Non-GAAP EPS of $1.25 beats by $0.13, revenue of $452.7M beats by $4.72M

Earnings History

Date EPS / Forecast Revenue / Forecast
February 11, 2022 -0.08 / 0.671 312M / 317.93M
November 1, 2021 0.23 / 0.5568 296M / 297.83M
August 3, 2021 0.43 / 0.5019 288.9M / 273.19M Beat!
May 5, 2021 0.33 / 0.5276 236.6M / 250.67M
February 4, 2021 3.58 / 0.6014 247.9M / 260.45M
November 9, 2020 -0.62 / -0.0194 258.5M / 282.7M
August 3, 2020 0.81 / 0.61 302.4M / 261.31M Beat!
May 6, 2020 0.39 / 0.54 237.1M / 226.53M Beat!
February 4, 2020 0.35 / 0.78 244.1M / 231.54M Beat!
November 4, 2019 0.56 / 0.66 222.09M / 211.97M Beat!
July 29, 2019 0.54 / 0.19 183.58M / 161.79M Beat!
April 29, 2019 -1.12 / -0.78 138.4M / 136.76M Beat!
February 5, 2019 0.19 / 0.18 131.49M / 132.34M
Date Price Open High Low Vol Change
Jan 29 150.68 150.36
153.34
149.08
992K -0.02%
Jan 28 150.71 149
152.62
148.26
1.1M 1.70%
Jan 27 148.19 147.2
151.53
147.2
1.4M -0.36%
Jan 24 148.73 146.4
149.18
145.97
946K 0.78%
Jan 23 147.58 146.76
148.72
146
757K 0.56%
 
Jan 22 146.76 146.1
147.18
145.31
695K 0.60%
Jan 21 145.88 144.57
146.27
143.48
1.2M 1.83%
Jan 17 143.26 142.85
144.82
141.57
977K 0.94%
Jan 16 141.92 142.75
143.5
140.73
776K -0.45%
Jan 15 142.56 140.48
142.64
138.65
829K 2.19%
Jan 14 139.51 142.46
144.24
139.39
985K -2.46%
Jan 13 143.03 141
144
138.46
1.2M 1.51%
Jan 10 140.9 137.75
142.83
137.49
1.1M 1.58%
Jan 8 138.71 137.62
139.2
137
899K 0.84%
Jan 7 137.55 137.73
139.43
136.84
962K 0.51%
Jan 6 136.85 138.3
139.72
136.13
1.1M -0.91%
Jan 3 138.1 138.32
139.52
137.17
745K 0.17%
Jan 2 137.86 137.07
139.46
136.72
853K 1%
Dec 31, 2024 136.5 138.1
138.85
136.01
690K -0.41%
Dec 30, 2024 137.06 138.07
138.65
136.96
748K -1.71%
Dec 27, 2024 139.44 139.09
139.82
138.34
603K 0.29%
Dec 26, 2024 139.03 135.98
139.1
135.93
921K 1.83%
Dec 24, 2024 136.53 137.51
138.12
135.84
341K -0.34%
Dec 23, 2024 136.99 135.37
137.11
132.83
1.3M 1.16%
Dec 20, 2024 135.42 134.98
137.01
134.12
2.3M 0.34%
Dec 19, 2024 134.96 135.52
136.37
133.26
983K -0.36%
Dec 18, 2024 135.45 137
140
134.26
2.1M -0.91%
Dec 17, 2024 136.69 132.51
137.24
132.1
1.6M 2.74%
Dec 16, 2024 133.05 127.67
134.81
127.35
1.7M 5.01%
Dec 13, 2024 126.7 126.7
127.05
125.61
782K -0.07%
Dec 12, 2024 126.79 128.22
128.63
126.63
554K -1.12%
Dec 11, 2024 128.22 129
129.68
127.29
725K -0.57%
Dec 10, 2024 128.96 129.67
130.48
127.58
805K -0.12%
Dec 9, 2024 129.12 128.33
129.42
128.02
683K 0.76%
Dec 6, 2024 128.14 126.96
128.93
126.96
548K 1.36%
Dec 5, 2024 126.42 126.82
128
125.74
540K -1.03%
Dec 4, 2024 127.74 125.47
127.9
125.21
705K 1.83%
Dec 3, 2024 125.44 125.41
126.98
125.26
751K -0.36%
Dec 2, 2024 125.89 126.16
128
125.76
820K -0.68%
Nov 29, 2024 126.75 126.15
127.07
125.5
403K 0.13%
Nov 27, 2024 126.59 127.91
128.27
125.43
740K -1.03%
Nov 26, 2024 127.91 127.15
128.14
124.23
758K 0.63%
Nov 25, 2024 127.11 125.94
127.81
125.01
1.6M 1.16%
Nov 22, 2024 125.65 125.18
127
124.38
1.2M 0.52%
Nov 21, 2024 125 123.27
126.13
122.37
1.2M 1.39%
Nov 20, 2024 123.29 119.36
124.01
118.91
1.4M 3.49%
Nov 19, 2024 119.13 116.34
119.79
115.27
1.1M 1.28%
Nov 18, 2024 117.62 117.46
118.32
116.33
1.0M 0.15%
Nov 15, 2024 117.44 122.1
122.69
117.36
1.3M -4.43%
Nov 14, 2024 122.88 125.53
125.89
122.58
877K -2.1%
Nov 13, 2024 125.51 127.19
127.84
125.51
807K -1.18%
Nov 12, 2024 127.01 126.95
128.24
126.39
893K -0.13%
Nov 11, 2024 127.17 125.76
129.67
125.75
1.3M 1.14%
Nov 8, 2024 125.74 124.91
126.28
123.76
562K 1.42%
Nov 7, 2024 123.98 125.29
126.65
123.5
755K -1.05%
Nov 6, 2024 125.3 124.1
126.48
122.47
1.2M 3.10%
Nov 5, 2024 121.53 120.01
122
119.08
748K 0.83%
Nov 4, 2024 120.53 121.27
122.32
119.7
1.0M -1.37%
Nov 1, 2024 122.21 120.52
123
120.52
1.5M 1.61%
Oct 31, 2024 120.27 122.52
123.04
119.42
1.4M 0%